Lilly osteoporosis drug recommended for breast cancer

A Food and Drug Administration advisory panel has recommended approving Eli Lilly and Co.’s Evista osteoporosis drug for cutting the risk of cancer in post-menopausal women with osteoporosis and post-menopausal women at high risk for breast cancer.

The non-binding recommendation follows an announcement from Lilly earlier this month that Evista reduced the risk of certain invasive breast cancers in post-menopausal women.

Lilly is looking for more uses for the drug, which generates $1 billion a year in sales, because it expects sales to weaken in the next several years. A patent on the drug expires in 2014.

Please enable JavaScript to view this content.

Story Continues Below

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our updated comment policy that will govern how comments are moderated.

{{ articles_remaining }}
Free {{ article_text }} Remaining
{{ articles_remaining }}
Free {{ article_text }} Remaining Article limit resets on
{{ count_down }}